# A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Study · id `cardio:ct-nct04732221` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04732221](<https://clinicaltrials.gov/study/NCT04732221>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04732221

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

## Technical summary

Registry record NCT04732221. Randomized; triple masking; primary purpose treatment. Start 2021-05-19 (actual); primary completion 2024-01-04 (actual). Results posted on 2025-02-21.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 168 participants (enrolled count; ClinicalTrials.gov record NCT04732221, source copy `cardio:ctgov-nct04732221-2025-05-25`, retrieved 2026-10-31)
- Started: 2021-05-19 (actual) (ClinicalTrials.gov record NCT04732221, source copy `cardio:ctgov-nct04732221-2025-05-25`, retrieved 2026-10-31)
- Primary completion: 2024-01-04 (actual) (ClinicalTrials.gov record NCT04732221, source copy `cardio:ctgov-nct04732221-2025-05-25`, retrieved 2026-10-31)
- Completion: 2024-07-02 (actual) (ClinicalTrials.gov record NCT04732221, source copy `cardio:ctgov-nct04732221-2025-05-25`, retrieved 2026-10-31)
- Results first posted: 2025-02-21 (ClinicalTrials.gov record NCT04732221, source copy `cardio:ctgov-nct04732221-2025-05-25`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Canada; Colombia; France; Germany; Greece; Israel; Italy; Mexico; New Zealand; Poland; Russia; Sweden; Türkiye; United Kingdom (ClinicalTrials.gov record NCT04732221, source copy `cardio:ctgov-nct04732221-2025-05-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04732221-2025-05-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
- Condition: Pulmonary Arterial Hypertension
- Condition: Hypertension, Pulmonary
- Intervention (Drug): Frespaciguat
- Intervention (Drug): Placebo to Frespaciguat
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study (`cardio:pubmed-39255991`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a8c0578e5d0a9d02f58c479aa9787ad5c963432e4a6f53e26c5ef1dc0d539406
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
